Actively Recruiting
Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial
Led by The George Institute · Updated on 2024-11-21
2000
Participants Needed
2
Research Sites
81 weeks
Total Duration
On this page
Sponsors
T
The George Institute
Lead Sponsor
U
University of Calgary
Collaborating Sponsor
AI-Summary
What this Trial Is About
Several clinical trials have produced variable conclusions regarding the effects of intensive blood pressure (BP) lowering in post-EVT acute ischaemic stroke (AIS) patients. Although two trials indicate harm from very intensive target-based treatment (SBP \<130 mmHg), the others neutral effects in the SBP range 140-160 mmHg. The ENCHANTED3/MT domain of the ACT-GLOBAL platform trial aims to test different approaches to the treatment of elevated SBP in post-EVT AIS patients to find an optimal BP management strategy. ENCHANTED3/MT will randomize (1:1:1) up to 2,000 patients with SBP ≥150 mmHg post-EVT to conservative (no or minimal SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP \[≥180mmHg\]), moderate (SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP \[150-160mmHg\]), or intensive (SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher) BP management.
CONDITIONS
Official Title
Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Received endovascular therapy within 24 hours of stroke symptom onset or last known well time
- Sustained systolic blood pressure of 150 mmHg or higher (two readings less than 10 minutes apart) within 3 hours after EVT
You will not qualify if you...
- Any definite contraindications to blood pressure lowering treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
The George Institute for Global Health
Sydney, New South Wales, Australia, 2000
Actively Recruiting
2
University of Calgary
Calgary, Alberta, Canada, T2N 1N4
Actively Recruiting
Research Team
X
Xiaoying Chen, PhD
CONTACT
C
Craig Anderson, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here